Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Clinical trial NCT04696055 · COMPLETED
Trial details
- NCT number
- NCT04696055
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-03
- Primary completion
- 2022-05-05
- Enrollment
- 95
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.